ABSTRACT
With the continued development of molecular biology technologies,circulating tumor DNA (ctDNA)has shown certain value in the diagnosis and treatment of malignant tumors. The emergence of next generation sequencing technology makes ctDNA detection more accurate and rapid. ctDNA plays a certain role in the early diagnosis,disease monitoring,therapeutic evaluation and medication guide of ovarian cancer by vir-tue of its safety and non-invasiveness. The application of ctDNA detection is insufficient at present,but with the continuous development of sequencing technology,ctDNA will play increasingly important roles in the diagno-sis,personalized treatment and prognosis evaluation of ovarian cancer.
ABSTRACT
Objective To explore the effect of setting up standardized treatment demonstration ward for cancer pain on the management of narcotic drugs. Methods The study group (from 2015 to 2016 to create the standardized treatment of cancer pain ward) and control group (from 2013 to 2014 to create a standardized pain treatment demonstration unit ) all kinds of narcotic drugs dosage and medication frequency (DDDs), a monthly 30 prescriptions from tumor anesthesia, analysis of prescription writing quality qualified the rate and the rate of unreasonable use. Results The study group of patients with cancer pain drug usage and DDDs, oxycodone dosage rises fast, DDDs way ahead, dosage of morphine increased gradually, morphine dosage gradually decreased, transdermal fentanyl DDDs decreased, pethidine dosage remains low. The research group for the passing rate of prescription writing quality 99.3％, the control group of prescription writing quality qualified rate is 81.1％, the research group of narcotic drug use rate was only 4％, reasonable utilization rate is as high as 96％ is not reasonable, unreasonable use of narcotic drugs control group was as high as 18.5％, reasonable utilization rate is only 81.5％ (P<0.05). Conclusion The creation of standardized pain treatment demonstration unit narcotic drugs more reasonable structure, can improve the quality of narcotic drugs prescription writing qualified rate, reduce the rate of unreasonable use, reasonable use of pain medicine has positive significance to ensure patient safety and efficacy of.
ABSTRACT
Objective:To observe the effect of simvastatin at different doses on the inflammatory factors and renal function in se-nile patients with diabetic kidney disease ( DKD) . Methods:Totally 160 cases of DKD patients were randomly divided into the control group, low dose group, conventional dose group and high dose group. All the patients were given the foundation treatment, and the low dose group, conventional dose group and high dose group was respectively given simvastatin 10, 20,40 mg·d-1 . The changes of in-flammatory cytokines (CRP, ICAM-1 and IL-1β) and renal index (BUN, Cr, UAER, 24hUpro and Uβ2-MG) among the groups were observed and compared before and after the 4-week treatment. Results:CRP in the high dose group after the treatment was significantly decreased when compared with that before the treatment and that in the control group after the treatment, and the difference was statisti-cally significant (P0.05). BUN in the four groups after the treatment had no obvious change when compared with that before the treatment, and there was no significant difference among the groups (P>0. 05). Cr and UAER in the four groups after the treatment were significantly decreased (P0. 05). Conclusion:Simvastatin can improve diabetic nephropathy conditions in two aspects of inflammation factors and renal in-dex, and simvastatin at high dose shows more advantages.